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Abstract 
AIM: This study aimed to confirm the role of f VEGF gene 936 C/T polymorphism and Diabetic Polyneuropathy 
(DPN) in the Indonesian population as well as to investigate its relationship with VEGF-A level and the role of 
vascular risk factors.  
MATERIAL AND METHODS: This was a cross-sectional study involving 152 subjects. Clinical symptoms and 
signs of DPN were examined using DNE and DNS scoring followed by nerve conduction study. All subjects 
underwent anthropometric, clinical examination and laboratory procedures to obtain body mass index, HbA1C 
level, lipid profile, Polymorphism of +936 C/T VEGF gene (PCR-RFLP technique), and VEGF-A plasma level 
(ELISA). Statistical analysis using a t-test or Mann-Whitney was performed to assess continuous data and Chi-
square for categorical data. Multivariate logistic regressions were also performed to determine the relationship 
between independent variables and DPN.  
RESULTS: Sixty-nine (45.4%) fulfilled the diagnostic criteria of DPN. There was a significant association between 
CT + TT genotype and DPN (OR 0.35 95%CI 0.16-0.79 p = 0.01). Multivariate logistic regression showed that 
plasma VEGF-A level (OR = 1.003; 95% CI = 1.000-1.007; p = 0.03), diabetes duration (OR = 1.108; 95% CI = 
1.045-1.175; p = 0.001), and CT+TT genotype (OR = 0.347; 95%CI = 0.148-0.817; p = 0.013) were associated 
with DPN. Sub-group analysis on subjects with HbA1C level ≥7% showed that VEGF-A (OR = 1.011; 95%CI = 
(1.004-1.017; p = 0.03), diabetes duration (OR = 1.245; 95% CI = 1.117-1.388; p < 0.001), CT + TT genotype (OR 
= 0.259; 95%CI = 0.074-0.911p = 0.035), with an adition of HDL (OR = 0.916; 95% CI = 0.857-0.978; p = 0.009) 
were significant predictors of DPN while LDL (OR = 1.017; 95% CI = 1.000-1.035; p = 0.053) acted as modifying 
factor.  
CONCLUSION: It appeared that CT + TT genotype of VEGF +936 gene might act as a protecting factor for DPN 
while VEGF-A, diabetes duration, HDL, and LDL acted as risk factors especially on subjects with HbA1C level ≥ 7. 
 
 
 
 
 
 
 
 
Introduction 
 
Diabetic polyneuropathy (DPN) is the most 
common complication of diabetes mellitus affecting 
the peripheral nervous system. It is associated with 
high morbidity and mortality rate and contributes to a 
decrease in quality of life [1] [2]. The global 
prevalence of DPN is 10% in the first year after the 
diagnosis and increases to approximately 50% after 
diagnosed with diabetes mellitus for 25 years [1] [3]. 
According to a study performed by Soewondo et al., 
(2010)
 
[4], it is predicted that around 63.5% of 
Indonesian diabetic patients treated in tertiary 
hospitals met the clinical diagnostic criteria of DPN. 
Data about risk factors associated with this fact is not 
well documented. Understanding this fact is crucial in 
the context of early detection and prevention. 
Growth factor imbalance as well as high blood 
glucose level and oxidative stress are believed to 
have a role in the pathogenesis of DPN as found in 
animal models. Of all those growth factors, special 
attention should be paid to the circulating Vascular 
Endothelial Growth Factor-A (VEGF-A). It is predicted 
of having a potentially neuroprotective capacity, but its 
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role is highly influenced by glucose level and oxidative 
stress. A previous study by Deguchi et al. (2009) 
found that VEGF level increased in the active phase 
of DPN but decreased in the advance phase [5]. This 
fact raised some doubt whether VEGF has a 
potentially beneficial role, or in reverse, is involved in 
the pathogenesis of DPN. 
It is believed that the genetic factor plays an 
important role in the development of DPN. Of all 
genetic variants associated with circulating VEGF 
level, the polymorphism of 936 3'UTR of VEGF gene 
has been studied and has shown various results. 
Zhang et al., (2014) found that the CC genotype was 
associated with an increased risk of developing DPN 
while CT and TT genotype was associated with a 
decreased risk. CC genotype also associated with a 
higher level of serum VEGF-A level [6]. On the other 
hand, Kim et al. (2009) found that there was no 
relationship between 936 C/T VEGF gene 
polymorphism with DPN although TT genotype was 
associated with higher plasma VEGF-A level [7]. 
Vascular risk factors such as high levels of 
HbA1C, total cholesterol, triglyceride and low level of 
HDL as well as obesity have also been associated 
with the risk of developing DPN [6] [8]. These suggest 
that DPN is a multifactorial condition, a combination of 
various factors such as metabolic, vascular, and 
genetics. 
   
 
Methods 
 
This was a cross-sectional study evaluating 
the relationship between polymorphism of VEGF gene 
936 C/T 3'UTR with DPN. It was conducted in Atma 
Jaya Academic Hospital, Jakarta between September 
2017 and March 2018. Participants were recruited 
consecutively and had undergone general and 
neurological clinical examinations, blood tests, and 
nerve conduction studies. Body mass index, blood 
pressure, results of the genetic test to evaluate 
polymorphism of VEGF gene 936 C/T 3'UTR, plasma 
VEGF-A level, HbA1C, lipid profile, and results of 
nerve conduction studies were documented. DNA 
analyses were performed in the Biomedical 
Laboratory of the School of Medicine Unika Atma 
Jaya Jakarta and the Laboratory of Medical 
Parasitology, Faculty of Medicine, Public Health, and 
Nursing Universitas Gadjah Mada Yogyakarta. The 
plasma VEGF-A level analysis was performed in 
Prodia Lab Jakarta, and other laboratory tests were 
done in the Clinical Pathology Department, School of 
Medicine, Unika Atma Jaya and Atma Jaya Academic 
Hospital. Nerve Conduction Studies (NCS) were 
performed in the Diagnostic Installation of Atma Jaya 
Academic Hospital. 
The inclusion criteria of the subjects were (1) 
adults diagnosed with type-2 diabetes mellitus aged < 
67 years, (2) willing to participate in the study and 
signed informed consent. The exclusion criteria were 
having (1) a diagnosis of chronic kidney disease 
and/or on routine hemodialysis, (2) a history of cancer 
or chemotherapy, (3) an acute exacerbation of chronic 
osteoarthritis, (3) peripheral arterial disease-defined 
by a manual ankle-brachial index of > 0.8, (4) acute 
stroke or myocardial infarction; (5) arrhythmias and or 
on cardiac pacemaker, (6) severe polyneuropathy 
(unrecordable NCS) or diabetic ulcer and/or history of 
diabetic ulcer, (7) a history of erectile dysfunction, 
constipation, and chronic diarrhea. 
This study was approved by the Medical and 
Health Research Ethics Committee (MHREC), Faculty 
of Medicine, Public Health, and Nursing Universitas 
Gadjah Mada. 
Diagnosis of DPN was established when the 
respondent had a positive result for at least one of the 
diagnostic evaluation. Diagnostic evaluation in this 
research was performed using (1) Diabetic 
Neuropathy Symptom (DNS) & Diabetic Neuropathy 
Examination (DNE) scoring and (2) NCS. DPN is 
considered positive if DNS score ≥ 1 and DNE score > 
3 while findings from NCS suitable to PDN in this 
research is (1) ≥ 1 abnormality on ≥ 2 separate nerves 
or (2) ≥ 1 abnormality on at least 2 nerves which must 
include the sural nerve [9] [10] [11]. General and 
neurological examinations as well as DNS and DNE 
scoring were performed by one specifically-trained 
physician and conducted before the NCS 
examination. NCS examinations were performed by a 
neurologist trained in EMG and Evoked Potentials.  
The HbA1C examination was performed using 
Boronat affinity binding method. Whole blood samples 
were mixed with reagents on Nycocard kit and read 
using a Nycocard
TM 
Reader. Total cholesterol, low-
density lipoprotein (LDL), high-density lipoprotein 
(HDL), and triglyceride levels were assessed using 
the Insert kit from Labtest on an automated 
biochemical analyser.  
 
Polymerase chain reaction-restriction 
fragment length polymorphism (PCR-
RFLP) 
DNA isolation from venous EDTA blood was 
performed using Wizard® Genomic DNA Purification 
Kit (Promega) product code A1120. The sequence for 
upstream and downstream primers were [12]: 
  forward: 5'-AAG GAA GAG GAG 
ACT CTG CGC3.' 
 reverse: 5'- TAT GTG GGT GGG 
TGT GTC TAC AGG-3.' 
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DNA amplification using PCR technique was 
performed using the kit Go Taq® Green Master Mix 
(Promega). PCR product was then digested using 
NlaIII enzyme with CutSmart
R
 buffer (New England 
Biolabs). Digested product and marker were analysed 
in 2% agarose gel using FloroSafe staining. After the 
electrophoresis process (110 V for 30 minutes), the 
result was then photographed and analysed. Digested 
products were (Figure 1): 
1) CC genotype: 1 band with product 
length 198 bp 
2) CT genotype: 3 bands with product 
length198 bp, 114 bp, and 84 bp 
3) TT genotype: 2 bands with product 
length 114 bp, dan 84 bp. 
 
Figure 1: A) Electrophoresis of PCR product showing 1 band 
(198bp); B) Electrophoresis of Digested PCR Product. CC genotype 
consists of 1 band (198 bp), CT genotype consists of 3 bands (198 
bp, 114 bp, and 84 bp) and TT genotype consists of 2 bands (114 
bp and 84 bp). Marker 100 bp on lane 1 
 
Plasma VEGF-A level was detected using 
ELISA method using ab119566-VEGFA Human 
ELISA kit from Abcam. Plasma was obtained from 
centrifuged venous EDTA blood (1500 rpm in 5 
minutes) and stored in a refrigerator (-70°C) before 
the procedure. All steps on the ELISA procedure was 
conducted according to the protocol written on the kit. 
All data were analysed using SPSS version 
22. Association between polymorphism of VEGF gene 
936 C/T and DPN was determined using Chi-square 
test. Association between numerical variables with 
genotype and DPN were evaluated using t-test if the 
data showed normal distribution and Mann-Whitney U 
test if not. Logistic regression analysis was then 
performed to evaluate the relationship between DPN 
and predictive factors, including genotype and 
vascular risk factors. 
 
 
Results 
 
There were 152 patients eligible as study 
participants. Ninety-eight participants (64.55%) were 
women, and 54 (35.5%) were men. More than half of 
the participants were 51-60 years (55.9%). Most of the 
participants (63.2%) were diagnosed with type-2 
diabetes for more than 5 years. Of all participants, 
45.4% fulfilled the diagnosis of DPN according to the 
protocol of this study. Majority of the respondents had 
HbA1C level ≥ 7% (65.1%). Hypertension was found 
in 88 (57.9%) of subjects, and 33 (21.7%) were 
obese. Fifty-two subjects (34.2%) had a cholesterol 
level of > 200 mg/dl, 108 (71.1%) had an LDL level of 
> 100 mg/dL, 95 (62.5%) had an HDL level < 40 
mg/dL, and 100 (65.8%) had a triglyceride level > 150 
mg/dL (Table 1).  
Table 1: Baseline characteristics of study subjects 
Characteristic n % 
Sex 
Men 
Women 
 
54 
98 
 
35.5 
64.5 
Age (years) 
<40  
41-50  
51-60  
>60  
 
7 
26 
85 
34 
 
4.6 
26.0 
55.9 
22.4 
Duration of diabetes diagnosis (years) 
≤ 5  
>5  
 
96 
56 
 
63.2 
36.8 
DPN Status 
DPN (-) 
DPN (+) 
 
83 
69 
 
54.6 
45.4 
HbA1C (%) 
< 7 
≥ 7 
 
53 
99 
 
34.9 
65.1 
Hypertension 
No 
Yes  
 
88 
64 
 
57.9 
42.1 
Body Mass Index (kg/m
2
) 
< 30, n= 119 (78.3%) 
≥ 30, n= 33 (21.7%) 
 
33 
119 
 
78.3 
21.7 
Total cholesterol (mg/dL) 
< 200 
≥ 200 
 
100 
52 
 
65.8 
34.2 
LDL (mg/dL) 
< 100 
≥ 100 
 
44 
108 
 
28.9 
71.1 
HDL (mg/dL) 
< 40 
≥ 40 
 
95 
57 
 
62.5 
37.5 
Triglyceride (mg/dL) 
< 150 
≥ 150 
 
52 
100 
 
34.2 
65.8 
Genotype Frequency 
CC 
CT 
TT 
 
115 
34 
3 
 
75.6 
22.4 
2 
 
The frequency of CC genotype was 75.6%, 
CT genotype 22.4% and TT genotype 2%. Genotype 
frequency fulfilled Hardy-Weinberg Equillibrium (2 = 
0.07; p = 0.787). There was a significant relation 
between CT+TT of VEGF +936 genotype and diabetic 
neuropathy (OR 0.35; 95%CI 0.16-0.79; p = 0.01) 
(Table 2).  
Table 2: The relationship between genotype of VEGF gene 936 
C/T polymorphism and DPN 
 DPN  
OR (95% CI) 
 
P DPN (-) 
n (%) 
DPN (-) 
n (%) 
Genotype CC 56 (67.5) 59 (85.5) 1 Reference 
CT+TT 27 (32.5) 10 (14.5) 0.35 (0.16-0.79) 0.01
*
 
 
Bivariate analysis of predictor variables in 
numerical data showed that the duration since 
diabetes diagnosis (in years) had a significant 
association with DPN [5(0-35) vs 3(0-25); p = 0.01] 
and body mass index had a significant association 
with CC genotype [27.23 ± 4.66 vs 25.28 ± 3.93; p = 
0.023)]. Another variable such as HbA1C level, total 
cholesterol, LDL, HDL, triglyceride, and body mass 
index failed to show statistical significance. One 
subject is excluded in analysis involving VEGF-A level 
due to an extreme outlier. A trend towards a higher 
level of plasma VEGF-A level in DPN group when 
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compared with non DPN group was observed [159.50 
(20.40-886.00) vs 136.10 pg/mL (17.50-631.40)] as 
well as between CT+TT vs CC genotype [166.10 
(17.50-522.50) vs 133.50 (20.40-886.00)] but not 
statistically significant (Table 3). 
Table 3: Bivariate analysis on the association of predictor 
variables with DPN and genotype of VEGF Gene 936 C/T 
polymorphism 
 
Variable 
DPN Status  
p 
Genotype  
 
P 
Non-DPN DPN CC CT+TT 
Diabetes 
Diagnosis 
duration 
(years) 
3.00 
(0-25) 
5.00 
(0-35) 
0.001 4.00 
(0-35) 
4.00 
(0-25) 
0.755 
HbA1C (%) 7.5 
(5.0-15.0) 
8.0 
(4.0-15.0) 
0.110 7.8 
(4.9-15.0) 
7.6 
(4.0-14.9) 
0.526 
Total 
Cholesterol 
(mg/dL) 
190 
(123-287) 
189 
(92-346) 
0.517 189 
(92-346) 
193 
(123-249) 
0.854 
LDL (mg/dL) 115 ± 30 
 
120 ± 39 0.347 119 ± 35 112 ± 33 0.305 
HDL (mg/dL) 43 
(30-85) 
42 
(30-83) 
0.119 42 
(30-83 
44 
(30-85) 
0.149 
Tryglyceride 
(mg/dL) 
129 
(65-636) 
131 
(67-330) 
0.530 130 
(67-636) 
131 
(65-265) 
0.940 
BMI (kg/m2) 26.95 ± 4.73 
 
26.53 ± 4.37 0.573 27.23 ± 4.66 25.28 ± 3.93 0.023 
VEGF – A 
(pg/mL) (n = 
151) 
136.1 
(17.50-
631.40) 
159.50 
(20.40-886.00) 
0.202 133.50 
(20.40-886.00) 
166.10 
(17.50-522.50) 
0.171 
 
Multivariate logistic regression showed that 
plasma VEGF-A level (OR = 1.003 (1.000-1.007); p = 
0.03), duration since diabetes diagnosis (OR = 1.108; 
95%CI = 1.045-1.175; p = 0.001), and CT+TT 
genotype (OR = 0.347; 95%CI = 0.148-0.817; p = 
0.013) were associated with DPN (Table 4).  
Table 4: Multivariate logistic regression of to predict DPN in all 
subjects (n = 151) 
Predictors  B SE Wald OR (95% CI) p 
 VEGF-A 0.003 0.002 4.684 1.003 (1.000-1.007) 0.03 
CT+TT Genotype -1.057 0.436 5.865 0.347 (0.148-0.817) 0.015 
Diagnosis duration 0.103 0.030 11.805 1.108 (1.045-1.175) 0.001 
 
Sub-group analysis on subjects with HbA1C 
level ≥ 7 (Table 5) indicated a similar relationship, 
showing that VEGF-A (OR = 1.011; 95%CI = (1.004-
1.017; p = 0.03), diabetes duration (OR = 1.245; 95% 
CI = 1.117-1.388; p < 0.001), CT+TT genotype (OR = 
0.259; 95%CI = 0.074-0.911, p = 0.035), with an 
adition of HDL (OR = 0.916; 95% CI = 0.857-0.978; p 
= 0.009) were significant predictors of DPN while LDL 
(OR = 1.017; 95% CI = 1.000-1.035; p = 0.053) acted 
as modifying factor. 
Table 5: Multivariate logistic regression to predict DPN in 
subjects with HbA1C ≥ 7 (n = 98) 
Predictors B SE Wald OR (95% CI) p 
VEGF-A 0.011 0.003 10.061 1.011 (1.004-1.017) 0.001 
CT+TT Genotype -1.349 0.614 4.433 0.259 (0.074-0.911) 0.035 
Diagnosis duration 0.219 0.055 15.682 1.245 (1.117-1.388) <0,001 
HDL -0.088 0.034 3.735 0.916 (0.857-0.978) 0.009 
LDL 0.017 0.009 0.628 1.017 (1.000-1.035) 0.053 
 
 
Discussion 
Of all 152 subjects, in regards with 
polymorphism of VEGF gene 936 C/T, we found that 
the frequency of CC genotype was 75.6% and CT+TT 
genotype was 24.4%. The frequency of genotype 
variation (CC vs CT+TT) for polymorphism of VEGF 
gene 936 C/T (rs3025039) in general population is 
75.1% vs 24.9%, East Asia 68.9% vs 31.1%, and 
South Asia 79.1% vs 20.1% [13]. In this study, it was 
observed that the genotype frequency of VEGF gene 
936 C/T polymorphism was close to the general 
population. Hardy-Weinberg analysis showed 2 = 
0.07; p = 0.787 meaning that the genotype frequency 
fulfilled the Hardy-Weinberg Equilibrium. 
This study found that the CT+TT genotype of 
VEGF gene 936 C/T polymorphism is associated with 
the decreased odds of DPN, hence can be considered 
as having a protective effect. This finding is consistent 
with a previous study performed by Zhang et al. 
(2014) [6], in which the CC genotype was correlated 
with a higher level of plasma VEGF-A. The exact role 
of VEGF gene 936 C/T polymorphism in DPN remains 
controversial. Another study performed by Kim et al. 
(2009) [7] found that there was no significant 
relationship between VEGF gene 936 C/T 
polymorphism and DPN although DPN and TT 
genotype correlated with higher plasma VEGF-A level. 
Another Single Nucleotide Polymorphism (SNP) 
regarding VEGF gene at the position of 7C/T found to 
be associated with DPN. The allele C was considered 
probably related to increased risk of developing DPN 
while allele T might be protective [14]. The exact 
mechanism of the potentially protective effect of T 
allele in this SNPs is still unclear [6] [14]. 
Although this study failed to reach a statistical 
significance, a higher median of VEGF-A level was 
observed in subjects with DPN and CT+TT genotype. 
These findings support the results of the study by Kim 
et al., (2009) [7]. It is presumed that the VEGF gene 
936 C/T polymorphism is somehow related with the 
AP-4 binding protein of VEGF gene which determines 
the level of circulating VEGF. Deguchi et al., (2009) 
revealed that the circulating VEGF level increased in 
the early and symptomatic stage of DPN and 
decreased later at an advanced stage [5]. The positive 
relationship between VEGF-A level and DPN from 
multivariate logistic regression analysis was found in 
this study supports this finding.  
Another interesting finding from this study is 
the significant association between polymorphism of 
VEGF gene 936 C/T with body mass index. CC 
genotype had a significantly higher BMI compared 
with CT + TT genotype (27.23 ± 4.66 vs 25.28 ± 3.93; 
p = 0.023) (Table 2). The previous study on 
obstructive sleep apnea failed to prove the 
relationship between VEGF gene 936 C/T 
polymorphism with obesity [15]. High VEGF-A level 
and VEGF-A overexpression are potentially protective 
towards obesity and insulin resistance. VEGF-A also 
has a role on the thermogenesis of brown adipose 
tissue (BAT) which plays a role in the development of 
obesity [16]. This study found that the level of VEGF-A 
on CT + TT genotype is higher compared with CC 
genotype. Although the difference was not statistically 
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significant, this could somehow explain the 
relationship between VEGF gene 936 C/T 
polymorphism with BMI. More studies are still needed 
to confirm this finding 
The increase in VEGF expression in the early 
stage of DPN is a response to hypoxia and oxidative 
stress. The target of this process is the endothelial 
cells, with proliferation and angiogenesis/ 
neovascularisation as a result. VEGF through 
VEGFR2 also plays the neuroprotective role together 
with other angioneurins such as IGF1, TGF beta 1, 
EPO, FGF2, HGF, EGF, and PGRN. These 
substances are believed to have a positive effect on 
remyelination and neurogenesis. These facts support 
the concept that VEGF has a dual effect, involved in 
pathogenesis as well as protecting the nerves in DPN 
[5] [17]. The fact that VEGF-A had a positive but small 
effect on the relationship with the occurrence of DPN 
could be explained by this concept. 
The regression model in this study showed 
that the interaction of VEGF gene 936 C/T 
polymorphism with diagnosis duration and vascular 
factors especially blood lipids plays an important role 
in the development of DPN. In subjects with HbA1C ≥ 
7%, LDL, HDL, and duration of diabetes diagnosis 
had a positive effect on the development of PDN. 
These findings have a clinical/practical implication, 
meaning that prevention strategy can be focused on 
individuals with high HbA1C, high LDL level, low HDL 
level, and longer duration of diabetes diagnosis. 
Dislipidemia considered as an important risk 
factor of DPN [18]. Lipid levels are related with the 
accumulation of sorbitol, formation of oxidised lipids 
and PARP, and activation of lipoxygenase on 
peripheral nerve fibres. Free fatty acids cause toxicity 
on neuronal cell and Schwann’s cells and also trigger 
the release of proinflammatory cytokines causing 
neuronal inflammation. Lipids are also related to 
insulin resistance of which in type-2 diabetic patients 
may worsen the hyperglycemic state. The peripheral 
nerve tissue expressed oxidised LDL (oxLDL) 
scavenger receptor. The receptors internalise oxLDL 
and glycated LDL which triggers inflammatory signals, 
causing NADPH oxidase inactivation which may 
cause increased oxidative stress [19] [20]. Lower HDL 
level has been proven to be associated with DPN and 
means that management to dislipidemia plays an 
important role in preventing and treatment of DPN 
[21]. 
To our knowledge, this is the first study in 
regards to VEGF gene 936 C/T polymorphism in a 
diabetic subject in Indonesia. There were some 
limitations to this study. Outliers of the VEGF-A level 
might show that excluding conditions, of which some 
of them relied only on medical record, such as acute 
on chronic OA, history of cancer, acute stroke and 
acute myocardial infarction were not enough to avoid 
extreme values of VEGF-A level. It is necessary to 
add the items on exclusion criteria such as smoking 
(active or passive), alcoholism, and other situation 
that could interfere with VEGF-A level. The diagnostic 
criteria in this study were likely only to accommodate 
mild DPN. Hence the result of this study can only be 
applied to those group. This study did not compare 
the genotype frequency between diabetic and normal 
subjects. Nevertheless, some previous studies have 
proved that polymorphism of VEGF gene 936 C/T did 
not associate with diabetes mellitus [6] [22]. 
The CT+TT genotype of VEGF gene 936 C/T 
polymorphism is potentially protective, while the CC 
genotype may be associated with a higher risk of 
developing DPN. A trend of higher VEGF-A level in 
DPN and CT + TT genotype was observed. This study 
also suggested that VEGF-A has a potential role in 
the pathogenesis of DPN, especially from the vascular 
aspect. Vascular risk factors, especially HbA1C and 
LDL, and HDL, as well as diagnosis duration,  acted 
as modifying factors which interact with VEGF gene 
936 C/T polymorphism in the development of DPN. 
Further study is needed to reveal the 
relationship between VEGF gene 936 C/T 
polymorphism and the physiological function of 
peripheral nerve in DPN such as quantitative sensory 
testing or neuroesthesiometer value of each nerve. 
This is important to find out the influence of VEGF 
gene 936 C/T polymorphism on the physiology of 
peripheral nerve to reveal its protective mechanism. 
Further study towards other genetic variants related to 
glycemic and metabolic function, ethnicity, especially 
the ones presumably related to nerve structure and 
function is needed to find the strongest genetic factors 
associated with DPN.  
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